Fintech

Accord BioPharma's IMULDOSA® (ustekinumab-srlf) Now Preferred Under Cigna Healthcare Commercial Plans

Prnewswire·April 20, 2026 at 12:05 PM

/PRNewswire/ -- Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology and immunology therapies,...

Original Source

Prnewswire — www.prnewswire.com

Related in Fintech

Amazon, Anthropic Deepen AI Partnership
PYMNTS
Commercial Loans Show US Economy Defies Forecasts
PYMNTS
Zenskar Raises $15 Million for Agentic AI
PYMNTS
Apple Hardware Leader John Ternus to Succeed CEO
PYMNTS

Accord BioPharma's IMULDOSA® (ustekinumab-srlf) Now Preferred Under Cigna Healthcare Commercial Plans

Amazon, Anthropic Deepen AI Partnership

Commercial Loans Show US Economy Defies Forecasts

Zenskar Raises $15 Million for Agentic AI

Apple Hardware Leader John Ternus to Succeed CEO